|
SP3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.43929354282591E-15 |
| Normal-vs-Stage2 |
4.78620000299301E-08 |
| Normal-vs-Stage3 |
1.71751501909512E-13 |
| Normal-vs-Stage4 |
5.28466159721575E-14 |
| Stage1-vs-Stage2 |
9.168400E-01 |
| Stage1-vs-Stage3 |
2.000800E-01 |
| Stage1-vs-Stage4 |
1.224280E-03 |
| Stage2-vs-Stage3 |
3.367800E-01 |
| Stage2-vs-Stage4 |
2.114300E-02 |
| Stage3-vs-Stage4 |
8.620400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62959645777505E-11 |
| Normal-vs-AfricanAmerican |
6.06859999999765E-05 |
| Normal-vs-Asian |
5.32839994349388E-10 |
| Caucasian-vs-AfricanAmerican |
3.767000E-01 |
| Caucasian-vs-Asian |
9.461000E-01 |
| AfricanAmerican-vs-Asian |
3.959800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.86277684785819E-13 |
| Normal-vs-Female |
2.7046032080591E-11 |
| Male-vs-Female |
9.256600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.14595008429797E-12 |
| Normal-vs-Age(41-60Yrs) |
1.22124532708767E-15 |
| Normal-vs-Age(61-80Yrs) |
2.55284682282308E-12 |
| Normal-vs-Age(81-100Yrs) |
1.223800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.411400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.648800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.295200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.280600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.132600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.395000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.644100E-02 |
| Classical-VS-Follicular |
8.725200E-01 |
| Classical-VS-Other |
6.028800E-01 |
| Classical-VS-Normal |
7.10160041883512E-10 |
| Tall-VS-Follicular |
9.300300E-02 |
| Tall-VS-Other |
6.379000E-01 |
| Tall-VS-Normal |
8.15020273492451E-11 |
| Follicular-VS-Other |
7.091600E-01 |
| Follicular-VS-Normal |
2.02119998515826E-09 |
| Other-VS-Normal |
2.800200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.77395900588817E-15 |
| Normal-vs-N1 |
1.05748743095546E-12 |
| N0-vs-N1 |
5.993700E-02 |
|
|
